Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Tapper EB, Bonafede M, Fishman J, et al
Abstract Objective The aim was to evaluate the cost-effectiveness of oral and subcutaneous semaglutide versus other oral glucose-lowering drugs (i.e., empagliflozin, canagliflozin, and sitagliptin) for the management of type 2 diabetes (T2D) in Denmark using clinically relevant treatment intensification rules
Appetite remains reduced but you're learning what portions work for your new normal
Fortunately, there are several ways to make it more affordable
US$ 26.63
US$ 22.97
US$ 21.89
US$ 28.37
